This action effectively negated PCSK9 function and led to a significant reduction in bloodstream PCSK9 and the total cholesterol in rats when administered orally.391 Further, in a syngeneic mouse MC38 colon cancer model, Yuan et al. demonstrated the synergistic effect of combining PF-06446846 and an anti-PD1 antibody, resulting in marked suppression of tumor growth and a significant extension of OS for the treated mice.346 Nonetheless, the clinical applicability of PF-06446846 is constrained by its narrow therapeutic window between PCSK9 lowering and hematopoietic effects. Here, PCSK9 is linked to malignant colon neoplasm.